GET DAILY SIGNALSCardio Diagnostics Holdings (CDIO): Assessing the Path to +46% Toward $2.80
Key Takeaways
- The $2.80 level serves as a reference drawn from valuation commentary rather than a broad analyst consensus, since CDIO has limited credible, up-to-date price targets available.
- GuruFocus places the GF Value near $2.79, suggesting the shares have recently traded below that mark, though the company’s minimal revenue makes such estimates inherently uncertain.
- From a recent close around $1.92, reaching $2.80 would represent an approximate 46% advance, notable given the stock’s wide 52-week range of $0.97 to $7.91.
- Positive elements include new coverage agreements, the company’s own CLIA-certified lab, and the FDA’s September 2025 decision to rescind its laboratory-developed test rule.
- Key risks center on negligible revenue, ongoing cash burn, potential dilution via at-the-market offerings, and the lack of broad Medicare or commercial reimbursement.
- Additional details on Major News, Today’s Price Move, Forecast, and Earnings are available on related pages.
- Market insights can also be tracked through resources such as Trending AI Robots for shifting conditions across equities and ETFs.
How the $2.80 Reference Point Was Set
CDIO lacks a meaningful current analyst consensus. MarketBeat shows no aggregated target and notes only a “Sell” rating from Weiss Ratings, which does not supply the dated, named targets that normally feed into such aggregates. Older or scattered figures, including an outlier $60 target and a prior $4-to-$8 range, sit too far from present levels to serve as reliable benchmarks. In my view, the $2.80 figure therefore stems from publicly discussed valuation work rather than sell-side consensus.
GuruFocus has published a GF Value of roughly $2.79, an intrinsic-value model that indicated the stock was trading below its estimate. Because CDIO traded above $2.80 for much of early 2026, that level remains a realistic reference rather than an arbitrary one. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where the Stock Stands Today and What Would Be Required
CDIO closed near $1.92 on November 11, 2026, with a market capitalization of about $5.7 million. Closing the gap to $2.80 would call for an advance of roughly 46%. That move hinges almost entirely on execution—turning modest pilot wins into sustained, reimbursable test volume. Revenue stayed minimal at roughly $2,680 in the first quarter of 2026 and about $5,360 in the second, while net losses reached approximately $1.79 million and $1.5 million in those periods. A return toward the target would likely need clearer reimbursement traction or a financing step that bolsters confidence without heavy dilution.
Factors That Could Help the Stock Move Higher
Several developments may support sentiment. The company completed a 1-for-30 reverse split in May 2025 to maintain its Nasdaq listing, opened an in-house CLIA-certified laboratory in Iowa City, and secured coverage from Atlas Healthcare Physicians for the Epi+Gen CHD and PrecisionCHD tests. The FDA’s September 2025 rescission of its LDT rule shifted oversight back to CLIA standards and eased a regulatory concern for many diagnostics firms. Given the stock’s history of sharp, news-driven moves, favorable announcements can still influence price action noticeably.
Obstacles That Could Keep the Target Out of Reach
Challenges remain substantial. Revenue is essentially zero, the company has been unprofitable since inception, and management has indicated the need for further capital, which could involve additional ATM share sales. Most importantly, the tests still lack broad Medicare and commercial reimbursement codes, limiting provider incentives to adopt them. CDIO has also reported a material weakness in internal controls and faces potential claims tied to terminated banker agreements. Any of these issues could constrain the shares well below $2.80.
Technical Picture and Trading Behavior
Price action has been highly volatile. After surging above $7 in February 2026, the stock settled into a range mostly between $1.50 and $2.50 in subsequent months. The $2.50 area has served as recurring resistance, while the $1.50-to-$1.60 zone has offered support. A sustained push toward $2.80 would first need to clear $2.50, and the very low average volume leaves the stock susceptible to large percentage swings on modest trading activity. From what I see, monitoring volume alongside price levels remains useful here.
Time Frame and Items Worth Watching
With no solid analyst targets in place, there is no standard 12-month horizon to reference. Investors should instead track quarterly results, revenue trends, cash burn and balances, new reimbursement decisions, and any further ATM issuance. The next earnings report is expected in late November 2026. Regulatory updates on laboratory-developed tests and any litigation related to banker fees also merit attention. I’m watching this closely as commercialization milestones unfold.
Using AI Tools to Track Momentum
I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor low-liquidity names like this one. The platform applies artificial intelligence across thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and changing market conditions. For a volatile micro-cap, such a systematic approach can surface shifts in trend more efficiently than manual review alone, helping complement independent research without replacing it.
Final Thoughts
Can CDIO reach $2.80? The level is a publicly referenced valuation point, not an analyst consensus, and sits roughly 46% above the latest price—a meaningful move. The underlying technology and recent coverage agreements provide a commercial foundation, yet negligible revenue, persistent losses, dilution risk, and missing reimbursement codes present meaningful headwinds. With limited analyst coverage and a price history shaped largely by speculation, results will depend on execution. In my view, $2.80 is a scenario worth monitoring rather than an outcome to assume.
Exploring Tickeron AI Tools for Research
I frequently use Tickeron’s AI Daily Buy/Sell Signals when reviewing names with limited liquidity and high volatility. The tool applies AI-driven analysis to generate signals based on technical patterns and market shifts, which helps me cross-check momentum alongside my own review of fundamentals and news flow. It serves as one more data point in the research process rather than a standalone decision maker.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CDIO in upward trend: price rose above 50-day moving average on November 10, 2026
CDIO moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 22 of 24 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CDIO's RSI Indicator exited the oversold zone, 41 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 54 cases where CDIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CDIO as a result. In 44 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 23 of 38 cases over the following month. The odds of a continued upward trend are 61%.
Following a +13.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 53 of 136 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
Bearish Trend Analysis
The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CDIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CDIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement